Establishment Labs Holdings (NASDAQ:ESTA) has announced a pivotal development in its quest for U.S. market approval of its Motiva Implants.
According to a recent filing with the Securities and Exchange Commission (SEC), the U.S. Food and Drug Administration (FDA) has slated a pre-approval inspection of the company's manufacturing facilities for the second quarter of 2024.
This scheduled inspection marks a crucial milestone in Establishment Labs' regulatory journey, potentially paving the way for the approval of Motiva Implants in the United States.
Read More
#UnitedStates #News #Nasdaq #Food #SEC
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments